Expertise in
31
conditions

Dr. David L. Bajor

Oncology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
Expertise in
31
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

David Bajor is an Oncologist practicing medicine in Cleveland, Ohio.

Dr. Bajor is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Awake Craniotomy.

He is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 14 clinical trials. Dr. Bajor is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Uh Cleveland Medical Center
University Hospitals Portage Medical Center
University Hospitals Ahuja Medical Center
Uh Regional Hospitals
Parma Community General Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Additional Areas of Focus

Dr. Bajor has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Terminated
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 19, 2024
Intervention Type: Drug
Study Drugs: CB-839, Capecitabine
Study Phase: Phase 1/Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological
Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
View 9 Less Clinical Trials

62 Total Publications

Targeting of Wnt-β-Catenin Pathway in Recurrent Ameloblastoma.
Targeting of Wnt-β-Catenin Pathway in Recurrent Ameloblastoma.
Journal: The New England journal of medicine
Published: June 03, 2026
Similar Doctors
Expertise in
27
conditions
Dr. David M. Peereboom
Oncology | Hematology Oncology
Expertise in
27
conditions
Dr. David M. Peereboom
Oncology | Hematology Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Peereboom is an Oncologist and a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. Dr. Peereboom is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Glioma, Astrocytoma, and Bone Marrow Aspiration. Dr. Peereboom is board certified in United Council For Neurological Subspecialties, 2008. Dr. Peereboom is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
216-844-1228
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Afshin Dowlati is an Oncologist practicing medicine in Cleveland, Ohio. Dr. Dowlati is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Bone Marrow Aspiration. Dr. Dowlati is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required
Before you request

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Burke is an Oncologist practicing medicine in Cleveland, Ohio. Dr. Burke is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Familial Adenomatous Polyposis, Familial Colorectal Cancer, Colorectal Cancer, Colonoscopy, and Endoscopy. Dr. Burke is board certified in American Board Of Internal Medicine, 1993. Dr. Burke is currently accepting new patients.

Frequently Asked Questions about Dr. David L. Bajor

How do I make an appointment with Dr. David L. Bajor?

You can book an appointment with Dr. David L. Bajor by calling their office at 216-844-3951. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Bajor a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Bajor is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Bajor specialize in?

While Dr. David L. Bajor is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. David L. Bajor participate in research or clinical trials?

Yes. Dr. David L. Bajor has published 62 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. David L. Bajor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David L. Bajor accept my insurance?

Dr. David L. Bajor accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-3951 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bajor's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile